ADHD isn't a lack of attention — it's a difference in how the brain manages dopamine, regulates its own "mind-wandering" network, and responds to reward. Decades of neuroscience research have mapped out what's actually going on, and none of it is about effort or willpower.
It's a chemistry balance, not a deficit
The dopamine hypothesis is the most consistent theme in ADHD neuroscience. A controlled PET imaging study using the tracer C-11 altropane, in 47 treatment-naive, non-smoking, non-comorbid adults with and without ADHD, found significantly increased dopamine transporter binding in the right caudate — part of the striatum, the hub connecting the prefrontal cortex to the brain's reward and movement circuits — in the ADHD group.1 This isn't simply "too little" dopamine; it's a signalling imbalance that affects how the brain prioritises and sustains attention on tasks that aren't inherently stimulating.
It's worth being upfront that the single-mechanism version of this hypothesis is a simplification, and the paper's own authors say so — they note that in vivo neuroimaging findings on the dopamine transporter in ADHD "have been somewhat discrepant." Other PET studies using different tracers have found normal or lower transporter density in some ADHD samples, and the direction of the effect appears to depend on prior stimulant exposure, age, and which brain region is measured. Dopamine dysregulation is a well-replicated theme; a single universal dopamine signature that shows up identically in every person with ADHD is not. This is also part of why ADHD looks so different between individuals, and why it gets missed so often in women.
The prefrontal cortex — and its wiring to the rest of the brain — shows up differently
Structural and functional MRI studies consistently find differences in the prefrontal cortex — the region most responsible for planning, impulse control, working memory and sustained focus — in groups of people with ADHD. The largest task-based meta-analysis of this literature pooled 55 fMRI studies (39 in children, 16 in adults), and its result is more interesting than "the ADHD brain is underactive."2
In children, hypoactivation relative to comparison subjects appeared mostly in systems involved in executive function (the frontoparietal network) and attention (the ventral attentional network). But hyperactivation appeared too, predominantly in the default, ventral attention and somatomotor networks. In adults, hypoactivation was concentrated in the frontoparietal system while hyperactivation showed up in visual, dorsal attention and default networks. The authors' conclusion is explicitly that this "extends early models of ADHD pathophysiology that were focused on prefrontal-striatal circuits" — in other words, it is not one broken region but a coordination problem across several large-scale systems, some of which are doing more than they should, not less. Notably, that dysfunction was detected even in the absence of comorbid mental disorders or a history of stimulant treatment.
These differences show up reliably at the group level in research. They are not used to diagnose ADHD in an individual; diagnosis is a clinical process based on behaviour and history, not a brain scan — which is part of why assessment waits are what they are, and why telling ADHD from burnout takes a clinician rather than a questionnaire.
The mind-wandering network doesn't switch off properly
The brain has a "default mode network" — a set of regions, including the medial prefrontal cortex and posterior cingulate, that's active during rest and mind-wandering and normally quiets down when you switch to a focused, externally directed task. Research on adults with ADHD has found interference from this network into task-focused attention networks during sustained-attention tasks — weaker suppression that correlates with attention lapses — which may help explain why attention can drift even when someone is trying hard to concentrate.3 The 55-study meta-analysis above independently found default-network hyperactivation in both children and adults with ADHD, which points the same way.2 As with everything here, the effect size in any single scan is small — useful for understanding ADHD as a group phenomenon, not for spotting it in one person's brain images.
The reward system responds less to anticipation — and why that matters for daily focus
An event-related fMRI study using a child-friendly monetary incentive delay task compared 27 typically developing children, 24 children with ADHD, and 25 children with an autism spectrum diagnosis plus ADHD symptoms.4 Ventral striatum activity during reward anticipation was decreased in children with ADHD symptoms — and here is the part worth getting right — regardless of primary diagnosis. The reduced anticipatory activity showed up both in children whose primary diagnosis was ADHD and in children whose primary diagnosis was autism but who had ADHD symptoms.
What the study did not find, contrary to what an earlier version of this article claimed, is a dose-response relationship with symptom severity. In the authors' words: "there was no relationship between the degree of ADHD symptoms and activity in ventral striatum." What did correlate was parent-rated reward sensitivity in daily life — children rated as more sensitive to reward showed greater anticipatory striatal activity. So the finding is trans-diagnostic rather than graded: it travels with ADHD-like symptoms across diagnostic boundaries, without scaling up as those symptoms get more severe. That's a genuinely different, and arguably more interesting, claim than the one we made.
It is consistent with what's often described clinically as an "interest-based" nervous system — one that engages readily with novel or urgent tasks but struggles to sustain effort toward a distant payoff. That links to one of the more influential behavioural models in the field: the "delay aversion" hypothesis, formalised by Edmund Sonuga-Barke in a widely cited dual-pathway framework. The idea is that some ADHD attention difficulty isn't a pure executive-function problem at all, but a motivational one — a brain that finds waiting itself aversive, and that will do almost anything, including get distracted, to escape a delay.5 The model proposes that executive-function deficits and delay aversion are at least partially separate pathways to the same outward symptoms, which is part of why ADHD looks so different from one person to the next — one person's difficulty might be mostly about filtering distraction, another's mostly about tolerating boredom, and many people show both. It also overlaps heavily with why ADHD and sleep problems travel together.
So why do stimulant medications help — and what does that tell us?
Stimulant medications like methylphenidate work, mechanistically, by blocking the dopamine transporter — the same protein highlighted in the PET research above — which increases the amount of dopamine available in the synapse. A PET study using [11C]raclopride measured this directly and found that oral methylphenidate at an average dose of 0.8mg/kg significantly increased extracellular dopamine in the brain, shown by a 20% reduction in striatal D2 receptor availability (p<0.0005).6
One detail changes how that result should be read, and we left it out before: that study was conducted in 11 healthy controls, not in people with ADHD. It demonstrates what the drug does to a human brain; it does not demonstrate that it is correcting an ADHD-specific deficiency. That fits the broader and awkward fact that stimulant medications also improve attention and reduce impulsivity in people who don't have ADHD — so medication response by itself cannot be used as proof of what's different in an ADHD brain. Researchers describe methylphenidate's effect as amplifying spontaneously released dopamine and improving signal-to-noise in target neurons — making the wanted neural signal more distinct from background noise — rather than simply topping up a missing chemical. That's a meaningful distinction: it explains why the medication works without requiring the entire dopamine hypothesis to be settled. If you take ADHD medication and are considering supplements alongside it, what to know about combining them is the practical version, and the omega-3 evidence in adult ADHD is the most-asked-about nutrition question.
It's often a developmental delay, not a permanent deficit pattern
A landmark longitudinal brain-imaging study estimated cortical thickness at more than 40,000 cerebral points from 824 MRI scans acquired prospectively on 223 children with ADHD and 223 typically developing controls.7 Maturation progressed in a similar regional order in both groups — primary sensory areas peaking before higher-order association areas — but there was a marked delay in ADHD: the median age by which half of cortical points reached peak thickness was 10.5 years, versus 7.5 years in controls. The delay was most prominent in prefrontal regions important for attention and motor planning. That is a lag in the same trajectory, not a different trajectory.
That finding is often stretched further than it goes. It helps explain why ADHD presentation can change significantly from childhood into adulthood, and it is consistent with symptoms easing for some people over time — but the study measured cortical thickness, not symptom outcomes, so it cannot establish that symptom improvement is caused by the prefrontal cortex catching up. A large share of cases persist into adulthood in some form, which is why adult ADHD is now taken far more seriously clinically than it once was, and why so many people are only diagnosed late.
Where the science is still evolving
It's tempting to want one unified story — "ADHD is a dopamine problem" or "ADHD is a default-mode-network problem" — because it's tidy. The honest picture from the last two decades of imaging and genetics research is messier: ADHD appears to arise from the interaction of several partially independent brain systems (dopaminergic signalling, executive-control circuitry, default-mode regulation, and reward processing), and researchers still disagree about how much weight each deserves and how they interact across development. Genetic research also points to ADHD being highly polygenic — influenced by many genes of small individual effect rather than one "ADHD gene" — which fits a brain difference showing up across multiple systems rather than one clean pathway.
What this doesn't mean
None of this research supports characterising ADHD as damage, deficiency, or a lesser brain. It's a different pattern of development and regulation, well documented at the group level, that plays out differently in every individual. The research explains why standard advice like "just focus harder" misunderstands the underlying biology — but it isn't a basis for self-diagnosis, and it doesn't replace a proper clinical assessment. Nothing we sell treats ADHD, and the nutrition-and-attention evidence is a good deal thinner than the supplement aisle suggests.
This article is for general information only and is not medical advice. Proco does not diagnose, treat, cure or prevent any condition. If you have concerns about attention, focus or ADHD, speak to a qualified healthcare professional.
References
- Spencer TJ, Biederman J, Madras BK, et al. Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane. Biological Psychiatry, 2007;62(9):1059-1061. pubmed.ncbi.nlm.nih.gov/17511972
- Cortese S, Kelly C, Chabernaud C, Proal E, Di Martino A, Milham MP, Castellanos FX. Toward systems neuroscience of ADHD: a meta-analysis of 55 fMRI studies. American Journal of Psychiatry, 2012;169(10):1038-1055. pubmed.ncbi.nlm.nih.gov/22983386
- Liu L, et al. Interference of default mode on attention networks in adults with attention-deficit/hyperactivity disorder and its association with genetic variants and treatment outcomes. CNS Neuroscience & Therapeutics, 2024;30(8):e14900. pmc.ncbi.nlm.nih.gov
- van Hulst BM, de Zeeuw P, Bos DJ, Rijks Y, Neggers SF, Durston S. Children with ADHD symptoms show decreased activity in ventral striatum during the anticipation of reward, irrespective of ADHD diagnosis. Journal of Child Psychology and Psychiatry, 2017;58(2):206-214. pubmed.ncbi.nlm.nih.gov/27678006
- Sonuga-Barke EJS. Causal models of attention-deficit/hyperactivity disorder: from common simple deficits to multiple developmental pathways. Biological Psychiatry, 2005;57(11):1231-1238. pubmed.ncbi.nlm.nih.gov/15949993
- Volkow ND, Wang GJ, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. The Journal of Neuroscience, 2001;21(2):RC121. (Conducted in 11 healthy controls.) pubmed.ncbi.nlm.nih.gov/11160455
- Shaw P, Eckstrand K, Sharp W, et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proceedings of the National Academy of Sciences, 2007;104(49):19649-19654. pnas.org
Related reading
- Adult ADHD in Ireland: What the Wait Actually Looks Like
- What the Research Actually Says About Nutrition and Attention
Want to know what's actually in what you take? Join the list — no spam, just it straight.